Government use licenses in Thailand: An assessment of the health and economic impacts

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Yamabhai, Inthira ^a   Mohara, Adun ^a   Tantivess, Sripen ^a   Chaisiri, Kakanang ^a   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DOCETAXEL; EFAVIRENZ; ERLOTINIB; IMATINIB; LETROZOLE; LOPINAVIR; RITONAVIR;

DATABASE; DRUG; ECONOMIC IMPACT; EMPIRICAL ANALYSIS; FOREIGN DIRECT INVESTMENT; GOVERNMENT RELATIONS; HEALTH IMPACT; HEALTH POLICY; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS; VOLUME;

ARTICLE; DRUG CONTROL; DRUG MARKETING; ECONOMIC EVALUATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; LICENCE; PRIORITY JOURNAL; QUALITY OF LIFE; THAILAND; UNITED STATES;

THAILAND;

EID: 80051594771     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-28     Document Type: Article

References (50)

1. World Trade Organization Agreement on trade-related aspects of intellectual property rights. 2001, Geneva: World Trade Organization, World Trade Organization., http://www.wto.org/english/docs_e/legal_e/27-trips.pdf
2. Correa CM. Bilateralism in intellectual property: defeating the WTO system for access to medicines. Case Western Reserve Journal of International Law 2004, 36:79-94.
3. 't Hoen E. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chicago Journal of International Law 2002, 3:27-46.
4. World Health Organization International Trade and Health: a reference guide 2009, New Delhi, India: World Health Organization, Regional Office for South-East Asia, World Health Organization.
5. Tangcharoensathien V, Tantivess S, Teerawattananon Y, Auamkul N, Jongudoumsuk P. Universal coverage and its impact on reproductive health services in Thailand. Reproductive Health Matters 2002, 10:59-69. 10.1016/S0968-8080(02)00087-3, 12557643.
6. Yamabhai I, Mohara A, Krichanan W, Chaisiri K, Tantivess S, Teerawattananon Y. Assessing the implications of Thailand's government use licenses, issued in 2006-2008. 2009, Nonthaburi: Health Intervention and Technology Assessment Program.
7. Wibulpolprasert S. Thailand Health Profile 2005-2007. 2008, Nonthaburi: Ministry of Public Health.
8. Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med 2007, 356:544-546. 10.1056/NEJMp068297, 17287474.
9. Ministry of Public Health and The National Health Security Office Facts and Evidences on the 10 Burning Issue Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand. 2007, Nonthaburi: Ministry of Public Health, Ministry of Public Health and The National Health Security Office.
10. Ministry of Public Health and The National Health Security Office The 10 burning questions regarding the Government Use of Patents on the four anti-cancer drugs in Thailand. 2008, Nonthaburi: Ministry of Public Health, Ministry of Public Health and The National Health Security Office.
11. Bate R. Thailand and the drug patent wars. Health Policy Outlook 2007, 5:1-7.
12. Kuanpoth J. Appropriate patent rules in developing countries-some deliberations based on Thai legislation. Journal of Intellectual Property Rights 2008, 13:447-455.
13. WHO Mission Improving access to medicines in Thailand: The use of TRIPS flexibilities. Bangkok, 31 January to 6 February 2008, WHO Mission., http://www.moph.go.th/hot/THAIMissionReport%20FINAL15feb08.pdf
14. Ministry of Public Health Notification of the Ministry of Public Health: Re: Exercising of right on pharmaceuticals products patent for imatinib, dated 25th January, B.E. 2551. 2008, Nonthaburi: Ministry of Public Health, Ministry of Public Health.
15. Thai Food and Drug Administration The volume of health products imported to Thailand. 2008, Nonthaburi: Ministry of Public Health, Thai Food and Drug Administration.
16. Bureau of Medical Development The clinical guideline for the diagnosis and treatment of acute coronary syndrome 2004, Nonthaburi: Department of Medical Service, Ministry of Public Health, Bureau of Medical Development.
17. Tamteeranon Y. Economic evaluation of HMG-CoA reductase inhibitor (statin) for primary prevention of cardiovascular diseases among Thai population. 2007, Nonthaburi: Health Intervention and Technology Assessment Program.
18. Population statistics. , http://www.dopa.go.th/stat/y_stat50.html
19. Population projections for Thailand 2001-2020. , http://web2.forest.go.th/stat/stat46/TAB65.pdf
20. International Health Policy Program Burden of disease and injuries in Thailand 2004. 2009, Nonthaburi, International Health Policy Program., http://www.thaibod.net/diseases.html
21. Cancer in Thailand. , http://www.nci.go.th/cancer_record/cancer_rec1.html
22. GIPAP Beneficiary in Thailand. , http://www.gipapthailand.org/apply.php
23. Service Quality Development Office Clinical practice guidelines for cancer. 2006, Bangkok: National Health Security Office, Service Quality Development Office.
24. Thai economy lost 2.5 billion due to CL. , http://unitcost.fda.moph.go.th/cl/news_detail.php?id=1317&type=2
25. Woranuj M, Phusadee A. Drug dispute could lead to trade trouble: US might downgrade Thailand on IP list. Bangkok Post 2007, 30. Bangkok.
26. Tongpakdi N, Sussangkarn C, Tinakorn P. Factors determining Thailand's export: Strategy for enhancing competitiveness. 1998, Bangkok: Thailand Development Reseach Institute.
27. U.S. imports for consumption 2008. , http://dataweb.usitc.gov/
28. Dacharux K, Leelapornchai P, Udomkerdmongkol M. Thailand's investment in the post-crisis era: issues and challenges. 2009, Bangkok: Bank of Thailand.
29. Trend of foreign direct investment in 2008. , http://www.kasikornresearch.com/TH/K-Econ%20Analysis/Pages/ViewSummary.aspx?docid = 15811
30. Investment Reserach. , http://portal.settrade.com/C17_ResearchList.jsp
31. Khor M. Patents, compulsory license and access to medicines: some recent experiences. Intellectual Property Right 2007, Penang, Malaysia: Third World Network.
32. Quick JD. Ensuring access to essential medicines in the developing countries: A framework for action. Clinical pharmacology and therapeutics 2003, 73:279-283. 10.1016/S0009-9236(03)00002-X, 12709717.
33. Dionisio D, Khanna AK, Nicolaou S, Raghavan V, Juneja S, Sengupta A, Messeri D. For-profit policies and equitable access to antiretroviral drugs in resource-limited countries. Future HIV Therapy 2008, 2:25-36.
34. Tantivess S, Kessomboon N, Laongbua C. Introducing government use of patents on essential medicines in Thailand, 2006-2007: Policy analysis with key lessons learned and recommendations. 2008, Nonthaburi: International Health Policy Program.
35. Treerutkuarkul A. Chaiya's plan for CL policy review hits major hurdle. Bangkok Post 2008, Bankok.
36. Rafiq S, Salim R, Bloch H. Impact of crude oil price volatility on economic activities: an empirical investigation in the Thai economy. Resources Policy 2009, 34:121-132.
37. Sally R. Thai trade policy: from non-discriminatory liberalisation to FTAs. The World Economy 2007, 30:1594-1620.
38. Thailand: The Golden Trade Opportunity. , http://www.thaitrade.com/home
39. Taylor CT, Silberston ZA. The economic impact of the patent system: a study of the British experience. 1973, Cambridge: Cambridge University Press.
40. Rozek RP. The effects of compulsory licensing on innovation and access to health care. Journal of World Intellectual Property 2000, 3:889-917.
41. Chien C. Cheap drugs at what price to innovations: does the compulsory licensing of pharmaceuticals hurt innovation?. Berkeley Technology Law Journal 2003, 835:4-10.
42. McFetridge DG. Intellectual Property Technology Diffusion, and Growth in the Canadian Economy. Competition policy and intellectual property rights in the knowledge based economy 1998, 65-104. Gallini RAaN: University of Calgary Press.
43. World Economic Outlook Database. , http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/index.aspx
44. Maleewong U, Kulsomboon V, Teerawattananon Y. The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. Journal of the Medical Association of Thailand 2008, 91:126-138.
45. Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. International Journal of Cardiology 2006, 109:307-316. 10.1016/j.ijcard.2005.06.026, 16026869.
46. Delea T, Karnon J, Sofrygin O, Thomas S, Papo N, Barghout V. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clinical Breast Cancer 2007, 7:608-618. 10.3816/CBC.2007.n.018, 17592673.
47. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs 1998, 9:899-907. 10.1097/00001813-199811000-00009, 9890701.
48. Carlson J, Reyes C, Oestreicher N, Lubeck D, Ramsey S, Veenstra D. Comparative clinical and economic outcomes of treatments for refractory non small cell lung cancer (NSCLC). Lung cancer 2008, 61:405-415. 10.1016/j.lungcan.2007.12.023, 18295368.
49. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: A systematic review and economic analysis. Health Technology Assessment 2004, 8:48.
50. Huse DM, Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G. Cost effectiveness of imatinib mesylate in the treatment of advance gastrointestinal stromal tumours. Clinical Drug Invest 2007, 27:85-93.